		<div class="wpcnt">
			<div class="wpa">
				<span class="wpa-about">Advertisements</span>
				<div class="u top_amp">
							<amp-ad width="300" height="265"
		 type="pubmine"
		 data-siteid="111265417"
		 data-section="1">
		</amp-ad>
				</div>
			</div>
		</div><p>Patients have been given the first dose of a potential antibody treatment designed to fight coronavirus.</p>
<p>Scientists developed the antibody in just three months after identifying it from blood taken from one of the first American patients to recover from Covid-19.</p>
<p>The immune system produces antibodies to fight off foreign invaders when it detects infection.</p>
<p>This medicine, referred to as LY-CoV555, emerged from the collaboration between Lilly and AbCellera to create antibody therapies for the prevention and treatment of coronavirus.</p>
<p>Researchers say it is the first potential new medicine specifically designed to attack SARS-CoV-2, the virus that causes Covid-19.</p>
<p>The first patients in the study were given the medication at major medical centres in the US including NYU Grossman School of Medicine and Cedars-Sinai in Los Angeles.</p>
<p>The placebo-controlled study will assess safety and tolerability in patients hospitalised with with the disease, and results are expected by the end of June.</p>
<p>A single dose of the medicine is administered via IV to up to 32 participants.</p>
<p>Mark Mulligan, director of the Division of Infectious Diseases and Immunology and director of the Vaccine Center at NYU Langone Health, said: “<i>We are committed to working with our industry partners to generate scientific evidence to meet the urgent need for treatments that reduce the severity of Covid-19 disease.</i>”</p>
<p>He added: “<i>Antibody treatments like the one being studied here hold promise to be effective medical countermeasures against this deadly infection.</i>”</p>
<p>Daniel Skovronsky, Lilly’s chief scientific officer and president of Lilly Research Laboratories, said: “<i>Antibody therapies such as LY-CoV555 may have potential for both prevention and treatment of Covid-19 and may be particularly important for groups hardest hit by the disease such as the elderly and those with compromised immune systems.</i>”</p>
<p>If the Phase 1 results show the antibody can be safely administered, researchers will move on to start studying LY-CoV555 in non-hospitalised Covid-19 patients.</p>
<p>Eli Lilly and Company also plans to study the drug in a preventative setting, focusing on vulnerable patient populations who historically are not optimal candidates for vaccines.</p>
<p>AbCellera and the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID) identified the antibody.</p>
			<div style="padding-bottom:15px;" class="wordads-tag" data-slot-type="belowpost">
				<div id="atatags-dynamic-belowpost-69028b8376403">
					<script type="text/javascript">
						window.getAdSnippetCallback = function () {
							if ( false === ( window.isWatlV1 ?? false ) ) {
								// Use Aditude scripts.
								window.tudeMappings = window.tudeMappings || [];
								window.tudeMappings.push( {
									divId: 'atatags-dynamic-belowpost-69028b8376403',
									format: 'belowpost',
								} );
							}
						}

						if ( document.readyState === 'loading' ) {
							document.addEventListener( 'DOMContentLoaded', window.getAdSnippetCallback );
						} else {
							window.getAdSnippetCallback();
						}
					</script>
				</div>
			</div>
Discover more from London Glossy Post
Subscribe to get the latest posts sent to your email.
